Factbox: Countries respond to heart inflammation risk from mRNA shots

3 minute read
Register now for FREE unlimited access to Reuters.com

Nov 10 (Reuters) - Some countries are limiting the use of COVID-19 shots based on so-called mRNA technology to younger people following reports of possible rare cardiovascular side-effects.

Europe's drug regulator said in July it had found a possible link between a very rare inflammatory heart condition and COVID-19 vaccines from Pfizer/BioNTech and Moderna (MRNA.O). read more

However, the benefits of mRNA shots in preventing COVID-19 continue to outweigh the risks, European and U.S. regulators and the World Health Organization have said.

Register now for FREE unlimited access to Reuters.com

Here are some of the steps some countries are taking:


The Public Health Agency of Canada said data suggested that reported cases of rare heart inflammation were higher after Moderna's vaccine compared with the Pfizer/BioNTech shots. read more


The Danish Health Agency said that it was continuing to offer Moderna's vaccine to under-18s, and that an earlier statement suggesting a suspension had been a miscommunication. read more


Finland paused the use of Moderna shots for younger people and instead would give Pfizer's vaccine to men born in and after 1991. It offers shots to those aged 12 and over. read more


France's public health authority has recommended people under 30 be given Pfizer's Comirnaty vaccine when available instead of Moderna, which carried comparatively higher risks of heart-related problems. read more


Germany's vaccine advisory committee has recommended people under 30 be vaccinated only with the Biontech/Pfizer vaccine as it showed a lower number of cases of heart inflammation in younger people than the Moderna shot. read more


A panel of health experts advising the government recommended in September children aged 12-17 should get only one dose of BioNTech's (22UAy.DE) vaccine after reports of heart inflammation as a side-effect. read more


Norway will hold off giving children aged 12-15 a second dose of a COVID-19 vaccine until it has gathered more research. On Oct. 22 the health ministry said there was no urgency given that children have a low risk of falling seriously ill from the disease. read more

On Sep. 2, Norway decided on giving one dose of the Pfizer/BioNTech vaccine to children aged 12-15. read more


Sweden has extended the pause of Moderna's vaccine beyond the original Dec. 1 deadline for people aged 30 and below due to rare heart-related side-effects, the public health agency said on Oct. 21.

The agency said earlier in October that data pointed to an increase of myocarditis and pericarditis among youths and young adults vaccinated with Moderna vaccine Spikevax, and paused its use for all born 1991 or later. read more


South Africa will start vaccinating children between 12 and 17 using the Pfizer (PFE.N) vaccine, the health minister said, as the country looks to ratchet up inoculations ahead of final-year examinations. read more

On the advice of its vaccine advisory committee the government would only give teenagers a single shot of Pfizer's normal two-shot regime due to concerns that it may affect the heart.


Britain has been offering all 12-15-year-olds a first a shot of the Pfizer/BioNTech vaccine. Second doses would not be offered to the age group until at least the spring when there may be more data from around the world. read more

Register now for FREE unlimited access to Reuters.com
Compiled by Antonis Triantafyllou Editing by Tomasz Janowski, Mark Potter and Nick Macfie

Our Standards: The Thomson Reuters Trust Principles.